SGLT2Is exert cardio-protective and reno-protective actions as well as have beneficial effects on metabolic parameters, including ALT levels.14 Significant improvements in liver enzymes was observed among Canagliflozin users as compared to placebo and Sitagliptin groups, slowing the progression of fatty liver in patients with T2DM.15 Local data regarding the effects of SGLT2Is on ALT levels are scarce; therefore, this study will provide evidence to assess their benefits in Pakistan. Here, GPT is linked to fatty liver disease.